Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLM-402
- Development stage
- Preclinical
- Lead developer
- Pelemed
- Modality
- Small Molecules
01
Overview
PLM-402 is a preclinical small molecule candidate developed by Pelemed for the treatment of chronic Hepatitis B virus (HBV) infection. It is designed with a dual mechanism of action, functioning as both a Class 1 Capsid Assembly Modulator (CAM) and an inhibitor of the Sodium/taurocholate cotransporting polypeptide (NTCP). As a Class 1 CAM, PLM-402 interferes with the viral replication cycle by inducing the formation of aberrant, non-functional polymers instead of proper nucleocapsids. Simultaneously, by targeting NTCP—the primary entry receptor for HBV and Hepatitis D virus (HDV) on hepatocytes—the drug aims to block the infection of healthy liver cells. This combined approach is intended to reduce the viral reservoir and prevent the spread of the virus, potentially offering a more effective treatment for chronic HBV patients.
Beyond the preview
Go deeper on PLM-402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLM-402.